Erika Hamilton: What Will We See at ASCO25 Breast Cancer Rapid Oral?
May 31, 2025, 03:01

Erika Hamilton: What Will We See at ASCO25 Breast Cancer Rapid Oral?

Erika Hamilton, Chair of Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on LinkedIn:

“What will we see at today’s ASCO25 Breast Cancer rapid oral?

Hall D2, 2:45-4:15pm CST

– TDXd Drug rechallenge after ILD
– sac-TMT 1st L TNBC – OptiTROP-Br05
– AI for pathologic assessment of HER-2
– Kat-6 inhibitor for ER+ MBC
– PI3 (gedatolisib) + trastuzumab for HER-2
– 2 abstracts around efficacy in brain metastasis
…and more.”

More posts featuring ASCO 2025.

ASCO 2025 ASCO25